MARKET

KIN

Kindred Bio
KIN
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-16.6727
48.17
5.27
420,526,441.50
Elanco Closes Acquisition of Kindred Biosciences
Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Kindred Biosciences. The transaction advances Elanco's access to the fast-growing $1+ billion dermatology market, complementing the company's existing pipeline ...
Business Wire · 08/30 10:45
Elanco Animal Health Closes Purchase of Kindred Biosciences for About $444 Million
MT Newswires · 08/30 07:41
--Stifel Nicolaus Downgrades Kindred Biosciences to Hold From Buy, Keeps $9 Price Target
MT Newswires · 08/20 16:24
DCF Advisers, LLC Buys VanEck Vectors Gold Miners ETF, Pfizer Inc, Kindred Biosciences Inc, ...
GuruFocus News · 08/16 20:38
Earnings Preview: Kindred Biosciences (KIN) Q2 Earnings Expected to Decline
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 19:04
INVESTIGATION ALERT: Monteverde & Associates PC Pursues Investigating the Following Merger
NEW YORK, NY / ACCESSWIRE / July 26, 2021 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire St...
ACCESSWIRE · 07/26 10:00
The Kindred Biosciences (NASDAQ:KIN) Share Price Is Up 142% And Shareholders Are Boasting About It
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
Simply Wall St. · 07/13 08:34
Insider Trends: Kindred Biosciences Insider Continues 90-Day Selling Trend
MT Newswires · 07/07 12:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KIN. Analyze the recent business situations of Kindred Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KIN stock price target is 9.50 with a high estimate of 11.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 128
Institutional Holdings: 35.06M
% Owned: 77.12%
Shares Outstanding: 45.46M
TypeInstitutionsShares
Increased
21
6.01M
New
32
9.34M
Decreased
22
7.83M
Sold Out
31
5.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
President/Chief Executive Officer/Director
Richard Chin
Chief Financial Officer/Secretary
Wendy Wee
Chief Scientific Officer
Hangjun Zhan
Director
Denise Bevers
Independent Director
Lyndon Lien
Independent Director
Nanxi Liu
Independent Director
Joseph McCracken
Independent Director
Herbert Montgomery
Independent Director
Raymond Townsend
Independent Director
Ervin Veszpremi
No Data

Webull offers kinds of Kindred Bio stock information, including NASDAQ:KIN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KIN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KIN stock methods without spending real money on the virtual paper trading platform.